Germany Cuts Pharma Rebate Level While Keeping Price Freeze
This article was originally published in The Pink Sheet Daily
German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.
You may also be interested in...
Drug price freeze introduced in 2010 would remain to 2022, under draft legislation to revise AMNOG reimbursement system. It introduces some limits on the year of free pricing that companies enjoy after launch.
Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.
Germany’s new grand coalition government includes a health minister with no background in health care.